Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04820322
Other study ID # GIL-1852
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 24, 2018
Est. completion date October 19, 2018

Study information

Verified date March 2021
Source MGP Ingredients, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Fibersym® is a RS4-type resistant modified wheat starch in which over 85% of the total starch is resistant starch as measured by AOAC method 991.43. It is meant to be consumed on a regular basis and doses up to 33g/day can be tolerated. The effect of a Fibersym-containing meal on postprandial glucose and insulin levels when compared to a control meal, where both meals contain the same amount of available carbohydrate, is not known. This study therefore investigated the acute effect of a Fibersym cookie and a control cookie matched for available carbohydrate after a 3-day habituation period.


Description:

The study used a double-blind, randomized, cross-over design. Visit 1: Participants willing to be considered were invited to come to the research centre to have the study procedures explained to them and be given a copy of the consent form which they may either sign then, take away to sign at a later date, or decline to participate. Participants were encouraged to ask any questions they may have and not to sign the consent form until all of their questions have been answered to their satisfaction. Those who consented to participate came to the research centre for a pre-selection visit when subject eligibility will be determined. A number of parameters were assessed including blood pressure, weight, height, BMI, and brief medical history. Visit 2-3: Eligible subjects were randomized using an online randomization calculator. Eligible subjects were studied on 2 separate days over a period of 6 weeks or less. Prior to each test meal, they were provided with enough cookies to consume 3 times/day over 3 days and instructed to start consuming the cookies 3 days before their visit. They were also provided with a calorie appropriate, standard frozen dinner to be consumed on the evening before their test meal. The interval between successive tests was no less than 6 days and no more than 4 weeks. On each test day, participants came to GI Labs in the morning after a 10-12 h overnight fast (except for water). Participants were asked to maintain stable dietary and activity habits throughout their participation and to refrain from drinking alcohol and from unusual levels of food intake or physical activity for 24 h before each test. Before the start of the test meal, subjects were asked whether they consumed the provided cookies over the last 3 days as instructed and the standard dinner the evening before. Subjects were asked to complete a 3- day record of supplement consumption and whether they consumed the standard evening meal, in addition to a 3-day symptom diary before each test visit. If any subject was not feeling well or had not complied with the preceding experimental conditions, the test was not carried out and was rescheduled for another day. On each test day, two fasting fingerprick blood samples were collected at -5 min and 0 min. Each sample consisted of 2 vials, one for glucose analysis and one for insulin analysis (4-8 drops of blood each). Questionnaires to record satiety and GI symptoms were administered. Participants were then given the test food together with 250 ml of water and instructed to consume them over 15 minutes. Additional blood samples were collected 15, 30, 45, 60, 90 and 120 min after the start of the test meal. Satiety questionnaires were administered at the same time intervals. GI symptom questionnaires were filled out at 2 h in addition to fasting. Test Foods: The sugar snap cookie formula (Control) was obtained from the American Institute of Baking (AIB) International (Manhattan, KS). Fibersym RW (Appendix 1) was added as an extra portion to the Control Cookie recipe, amounts were adjusted so that both the control and Fibersym cookie portions contained the same amount of available carbohydrate (ingredients are listed in appendix 1). Both cookies were baked at the facilities of AIB. The macronutrient composition of baked cookies was determined by an independent laboratory and the final weights of the cookies fed were adjusted accordingly. For the test breakfasts during the postprandial visit, the subject consumed approximately 3 cookies containing 40 g available carbohydrates, the weight of Control Cookies per meal was 78.1g whereas the weight of Fibersym Cookies per meal was 97.8 g (delivering 21 g of fiber from Fibersym and 2.1g from the flour) (Table 1). Both test meals were consumed with 250 ml of water. During the 3-day pre-feeding period, subjects consumed 108.9g cookies (approx. 3.5) of Control Cookies per day and 136.2 g of Fibersym Cookies (approx. 4) per day (delivering 29 g fiber from Fibersym/day). The cookies were consumed during the 3 meals (breakfast, lunch and dinner). Both the control and Fibersym cookies contributed 50g available carbohydrate per day. The product was re-packaged by a GI Labs staff member not involved in the clinical trial. Product label displayed the subject number, subject initials, product ID, ingredients statement, GIL repacked date, expiration date, researcher name and telephone number, investigational use statement, and allergy warnings (if needed). Study Product Intake Logs were completed upon dispensation of study product to each subject. After the data had been entered, checked for errors and the database locked, the code was broken, #149 corresponded to the control cookie while 394 corresponded to the Fibersym cookie. All subjects were asked to consume a standard evening meal provided by GI Labs and consisted of a frozen dinner.


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date October 19, 2018
Est. primary completion date October 19, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Male or non-pregnant females, 18-75 years of age, inclusive - Body mass index (BMI) between 18.5 and 35 kg/m² inclusive at screening. - Systolic blood pressure <130 mm Hg; Diastolic blood pressure <90 mm Hg. - Willing to maintain habitual diet, physical activity pattern, and body weight throughout the trial. - Willing to abstain from strenuous exercise, or consume alcoholic drinks 24 hours before study days. - Absence of health conditions that would prevent fulfillment of study requirements as judged by the Investigator on the basis of medical history. - Understanding the study procedures and willing to provide informed consent to participate in the study and authorization to release relevant protected health information to the study Investigator. - Female subjects; willing to use a contraceptive method to avoid pregnancy during the study period. Exclusion Criteria: - Failure to meet any one of the inclusion criteria - Smokers - Known history of diabetes, gastrointestinal, liver, kidney, or cardiovascular (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, stroke), and pulmonary disease - Use of medications known to influence carbohydrate metabolism, including, but not limited to adrenergic blockers, diuretics, thiazolidinediones, metformin and systemic corticosteroids within 4 weeks of the screening visit, or with any condition which might, in the opinion of Dr. Wolever, the president of GI Testing, either: 1) make participation dangerous to the subject or to others, or 2) affect the results. - Use of antibiotics within 4 weeks of start of study - Major trauma or surgical event within 3 months of screening. - Unwillingness or inability to comply with the experimental procedures and to follow GI Labs safety guidelines. - Known intolerance, sensitivity or allergy to any ingredients in the study products. - Extreme dietary habits, as judged by the Investigator (i.e. Atkins diet, very high protein diets, etc.) - Change in body weight of >3.5 kg within 4 weeks of the screening visit. - History of cancer in the prior two years, except for non-melanoma skin cancer. - Exposure to any non-registered drug product within 30 d prior to screening. - Pregnancy or breastfeeding - Any history of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, binge eating) diagnosed by a health professional

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Fibersym
RS4-type resistant modified wheat starch
Control cookie
control cookie

Locations

Country Name City State
Canada Glycemic Index Laboratories, Inc Toronto Ontario

Sponsors (2)

Lead Sponsor Collaborator
MGP Ingredients, Inc. Glycemic Index Laboratories, Inc

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary 2-hour postprandial glucose incremental area under the curve (IAUC) 2-hour postprandial glucose incremental area under the curve (IAUC) after the Fibersym-containing carbohydrate load with the control meal 2 hours
Secondary 2-hour postprandial insulin incremental area under the curve (IAUC) compare the 2-hour postprandial insulin incremental area under the curve (IAUC) after the Fibersym-containing carbohydrate load with the control meal 2 hours
Secondary Blood glucose concentration at each time point To compare the individual blood glucose concentrations at each time point after the Fibersym-containing carbohydrate load with those after the control meal 2 hours
Secondary Blood glucose increment at each time point To compare the individual blood glucose increments at each time point after the Fibersym-containing carbohydrate load with those after the control meal 2 hours
Secondary Serum insulin concentration at each time point To compare the individual serum insulin concentrations at each time point after the Fibersym-containing carbohydrate load with those after the control meal 2 hours
Secondary Serum insulin increment at each time point To compare the individual serum insulin increments at each time point after the Fibersym-containing carbohydrate load with those after the control meal 2 hours
Secondary Abdominal bloating To compare the occurrence of abdominal bloating (none, mild, moderate or severe) after the three days of pre-feeding of Fibersym cookies with the control meal 2 hours
Secondary Belching To compare the occurrence of belching (none, mild, moderate or severe) after the three days of pre-feeding of Fibersym cookies with the control meal 2 hours
Secondary Nausea To compare the occurrence of nausea (none, mild, moderate or severe) after the three days of pre-feeding of Fibersym cookies with the control meal 2 hours
Secondary Diarrhea To compare the occurrence of diarrhea (none, mild, moderate or severe) after the three days of pre-feeding of Fibersym cookies with the control meal 2 hours
Secondary Flatulence To compare the occurrence of flatulence (none, mild, moderate or severe) after the three days of pre-feeding of Fibersym cookies with the control meal 2 hours
Secondary Satiety scores To compare the satiety scores after the Fibersym-containing carbohydrate load with the control meal. Satiety is the mean of 4 measures, hunger, fullness, desire to eat and prospective consumption (how much do you think you can eat) each measured using visual analogue scales (VAS) at intervals over the postprandial period. A VAS is a 100mm line anchored at the left end with phrase indicating a high in tensity of the feeling (eg. as hungry as I have ever felt) and at the other end with a phrase indicating a low intensity of feeling (eg. not hungry at all). A lower score means that the subject is more satiated. 2 hours
See also
  Status Clinical Trial Phase
Completed NCT03932695 - Investigation of Milk Peptides on Postprandial Blood Glucose Profile N/A
Completed NCT03159065 - Postprandial Efficacy of Probiotic Fruit Beverages on Glucose Tolerance and Insulin Resistance N/A
Completed NCT04499287 - Mealtime Walking Study to Improve Postprandial Metabolic Response N/A
Completed NCT04063137 - Black Rice Anthocyanin in Mixed Meals: Influence on Postprandial Glycaemic and Lipid Responses Among Healthy Individuals N/A
Active, not recruiting NCT05460884 - Effects of Seaweed Extract on Postprandial Response to White Bread N/A
Completed NCT05405010 - Individually Timed Stair Climbing and Descending to Lower Postprandial Glucose N/A
Completed NCT05161182 - Westlake N-of-1 Trials for Macronutrient Intake 2 ( WE-MACNUTR 2) N/A
Completed NCT03989674 - Glycaemic Index (GI) Evaluation of Carbohydrate-based Food With Functional Ingredients Derived From Food Sources N/A
Completed NCT04125602 - Westlake N-of-1 Trials for Macronutrient Intake N/A
Completed NCT02896010 - Personalized Smartphone-assisted Coaching System to Improve Glucose Homeostasis in Adults With Prediabetes N/A
Completed NCT04476693 - Metabolic Responses to Breakfast in Adolescent Girls N/A
Completed NCT05231642 - Individualised Postprandial Glucose Responses in Type 1 Diabetes N/A
Completed NCT03374501 - Determination of the GI and II Values of Soft Drink and Soft Drink With Sugardown™ N/A
Completed NCT05000944 - Is Mid-morning Breakfast as Healthy as Early-morning Breakfast for Blood Sugar Control in Adolescent Girls? N/A
Recruiting NCT04243629 - Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System in Adults With Type 1 Diabetes N/A
Completed NCT04289545 - Postprandial Effects of Functional Bread N/A
Completed NCT04018976 - AVACEN Treatment Method and Postprandial Blood Glucose N/A
Completed NCT00771693 - Effects of Insulin Treatment on Postprandial Platelet Activation in Patients With Non-insulin-dependent Diabetes Mellitus (NIDDM) Phase 4
Completed NCT00930956 - Comparison of Different Types of Resistant Starch N/A
Recruiting NCT04419948 - Oleocanthal Rich Olive Oil Acute Effects on Hyperglycemia and Platelet Activation in T2DM N/A